SynthesisFrontiers in pharmacology2026
Impact of pharmacist intervention on therapeutic drug monitoring of vancomycin: a meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the impact of pharmacist interventions on the implementation and clinical efficacy of vancomycin therapeutic drug monitoring (TDM). Methods: A Cochrane systematic review methodology was employed. Databases including PubMed, Medline, Embase, Cochrane Library, CNKI, and Sinomed were searched. After quality assessment and data extraction of eligible clinical studies, Meta-analysis was performed using Stata 18.0 to compare the differences between the pharmacist intervention group and the non-pharmacist intervention group in terms of the incidence of acute kidney injury, clinical effective rate, 30-day mortality, correct blood sampling time rate, target blood concentration attainment rate, TDM sampling rate, etc. Results: A total of 63 studies were included in the Meta-analysis. The results showed that pharmacist interventions reduced the incidence of acute kidney injury (RR = 0.67, 95% CI = 0.57, 0.78, P < 0.05), improved the clinical effective rate (RR = 1.11, 95% CI = 1.06, 1.17, P < 0.05), reduced 30-day mortality (RR = 0.52, 95% CI = 0.33, 0.82, P < 0.05), increased the correct TDM blood sampling time rate (RR = 1.52, 95% CI = 1.25, 1.83, P < 0.05), increased the target blood concentration attainment rate (RR = 1.60, 95% CI = 1.49, 1.72, P < 0.05), increased the TDM sampling rate (RR = 1.65, 95% CI = 1.34, 2.04, P < 0.05), increased the proportion of dosage regimen adjustments based on TDM results (RR = 2.68, 95% CI = 1.93, 3.70, P < 0.05). There was no significant effect on the duration of medication, length of hospital stay or TDM timeliness. Subgroup analysis showed that In the 10-20 mg/L group and the group with no specified target range, the serum concentration attainment rate was improved under pharmacist intervention (RR = 1.61, 95% CI = 1.50, 1.73, P < 0.05; RR = 1.49, 95% CI = 1.07, 2.08, P < 0.05). In the groups defined by serum creatinine increase ≥0.5 mg/dL or ≥50% from baseline, and serum creatinine increase ≥0.3 mg/dL or ≥50% from baseline, pharmacist interventions reduced the incidence of acute kidney injury (RR = 0.58, 95% CI = 0.45, 0.74, P < 0.05; RR = 0.64, 95% CI = 0.48, 0.85, P < 0.05). Conclusion: This study indicates that in patients treated with vancomycin under TDM, pharmacist interventions can promote the standardization of vancomycin TDM, reduce the incidence of acute kidney injury, and improve clinical outcomes. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261301721, identifier CRD420261301721.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.